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Summary.-Changes in cell mediated and humoral immunity following the excision
of a transplantable melanoma growing in the footpad of its syngeneic host, as
measured by an in vitro cytotoxicity test, were assessed. Spleen cell cytotoxicity
did not change significantly. Cells from the regional lymph nodes stimulated
tumour growth before tumour excision. Three days following tumour excision
this stimulatory effect was undetectable. Loss of serum factors capable of blocking
the cytotoxicity of spleen cells occurred 24 h after tumour excision. Serum cyto-
toxicity increased after tumour excision to a maximum on the third day. Following
tumour excision the rise in serum cytotoxicity and loss of regional lymph node
tumour stimulation were concomitant with the loss of blocking activity.
SPECIFIC host immmunity to a growing
tumour is now well documented using
both in vivo (Prehn and Main, 1957;
Klein et al., 1960) and in vitro (review,
Hellstrom and Hellstr6m, 1971) method-
ology. Most studies show that both
peripheral blood and splenic lymphocytes
can inhibit tumour growth in vitro.
This cell mediated immunity may be
abrogated by sera from tumour bearing
animals. It has also been demonstrated
that the cell mediated immunity de-
creases and the serum blocking activity
increases later in tumour growth (Hell-
strom et al., 1973).
However, recent reports on the role
of the draining lymph node lymphocytes
appear to be contradictory. Using a
murine mammary tumour model, Medina
and Heppner (1973) described tumour
specific growth stimulation by lympho-
cytes derived from lymph nodes. Flan-
nery et al. (1973) demonstrated that the
regional lymph node cells exhibit early
cytotoxicity which decreases late in tu-
mour growth. Using a rat fibrosarcoma
model, Currie and Gage (1973) reported
continuing cytotoxicity in the regional
lymph node cells, although there was a
change from specific to nonspecific cyto-
toxicity later in tumour growth.
Tumour excision has been shown to
effect an increase or return ofcell mediated
immunity with a decline in serum blocking
factor (Heppner, 1972; Baldwin, Embleton
and Robins, 1973). Although Alexander
et al. (1969) demonstrated immunoblast
cells in the thoracic duct lymph after
tumour removal, the effect of tumour
excision on in vitro tumour growth
stimulation by regional lymph node cells
has not been described.
In a previous study using the mouse
melanoma model, it was reported that
spleen cell cytotoxicity was present at
the same time as regional lymph node
stimulation of tumour growth (Bartholo-
maeus et al., 1974). The aim of the
present experiments was to investigate
the changes in host cell mediated and
humoral immunity following excision of
the tumour at a stage when tumour
growth stimulation by the regional lymph
nodes was first demonstrable. The same
transplantable murine melanoma model
was employed except that the tumourTUMOUR EXCISION AND IMMUNITY
cells were inoculated into the footpad
and the resulting tumour excised before
metastatic spread to the regional lymph
nodes occurred.
MIATERIALS AND METHODS
Mice.-Inbred female C57BL/6J mice,
6-8 weeks old were used throughout this
study.
Tumour cell lines.-The B16 melanoma
arose spontaneously in a C57BL/6J mouse in
1954 (Green, 1968). It is maintained in
this laboratory by serial subcutaneous pas-
sage in C57BL/6J mice every third week.
This tumour metastasizes to the regional
lymph nodes and later to the lungs. How-
ever, at the time of tumour excision in this
experiment there was no lymph node
involvement.
Lewis lung tumour (LLT) is a non-cross-
reacting carcinoma Mwhich arose spontaneously
in a C57BL/6J mouse in 1951 (Sugiura and
Stock, 1955). It is maintained in this
laboratory in C57BL/6J mice by serial
subcutaneous passage.
Tissue culture cell lines. These were
established in RPMI 1640 (Grand Island
Biological Company, Grand Island, New
York, U.S.A.) ith 5%O foetal calf serum
(FCS) and buffered at pH 7-2 according to
the formula of Croce (Croce, Koprowski and
Eagle, 1972). Cells Mwere discarded after
10 passages in vitro and fresh lines established
from an in vivo passage. Single cell suspen-
sions were obtained by trypsinization with
0 25% trypsin in phosphate buffered saline
(PBS).
Inoculationt. A single cell suspension of
B16 melanoma cells was prepared by passing
non-necrotic pieces of tumour tissue through
a stainless steel mesh, allowing the larger
particles to settle for 5 min, then washing
the supernatant cells once in PBS. A
concentration of 1 x 107 viable cells/ml was
prepared anid 5 ,ul was inoculated into the
left footpad.
Lym]phoid cells anid sera. Sera and cells
prepared from normal non-tumour bearing
control and from tumour bearing groups
were pooled from 5 mice on each test day.
Animals were exsanguinated under ether
anaesthesia by bleeding from the axillary
artery and the sera wvere stored at -20°C.
Spleen cell suspensions vwvere made by
passing the spleens through a staiiiless steel
mesh into Hanks' balanced salt solution
(HBSS), allowing the debris to settle for
5 min, and layering the supernatants on to
a Ficoll-Hypaque gradient (Penper, Zee and
Mickelson, 1968). This was spun at 1000 g
for 15 min and the mononuclear cells Nhich
banded at the interface were removed.
Lymph nodes were dissected from the
left popliteal fossa and minced with scissors
before aspirating through an 18 gauge
needle into HBSS. The debris was allowed
to settle for 5 min, after which the super-
natant cells were harvested.
Cells from both sources were w%ashed
3 times in HBSS and resuspended at a
concentration of 5 x 106 cells/ml in buffered
RPMI 1640.
Cytotoxicity assay.-This was based on
the method of Takasugi and Klein (1970)
using Falcon microtest tissue culture trays
(No. 3034 Falcon Plastics, New York,
U.S.A.) modified as previously described
(Bartholomaeus et al., 1974). Briefly, 5 ,ul
of lymphoid cell suspensions Nere added to
each wrell, folloNwed by 5 1l of B16 melanoma
or LLT tissue culture cells at a concentration
of 4 x 104 viable cells/ml, in buffered
RPMI 1640 with 10% foetal calf serum.
The trays were incubated for 36 h at 37°C
with 50o CO2, then inverted for 4 h to allow-
debris and non-viable cells to fall away from
the bottom of each well. The trays were
processed by flooding the plates once with
PBS, gentle decanting, immersing in methan-
ol for 15 min and subsequently staining
with Giemsa stain. The number of target
cells remaining in each well was counted
under x 80 magnification. B16 melanoma
cells were readily identified by their large
size and abundant pink staining cytoplasm.
LLT 'cells were smaller and more densely
staining but quite distinct from lymphocytes
and macrophages. Ten replicates of each
culture were prepared.
Serunm cytotoxicity. All sera were heat
inactivated at 56°C for 30 min, diluted
1: 2 with culture medium and passed
through an 0 45 ,um millipore filter. Normal
guinea-pig serum, diluted 1: 5 in culture
rnedium and sterilized by passage through a
millipore filter was used as the source of
complement. To determine serum cyto-
toxicity, 5 ,tl of medium containing B16
melanoma cells and 5 ,ul of serum w%ere
incubated for 1 h at 37°C. 5 ,ul of com-
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plement was added and the trays were
incubated at 37°C under 5% CO2 for 24 h
and processed as described above.
Detection of blocking factors.-In experi-
ments to test for the presence of serum
factors capable of blocking the cytotoxicity
ofimmune spleen cells against B16 melanoma
cells, 5 ,ul of melanoma cells in culture
medium and 5 ,ul of serum diluted 1: 2 in
buffered RPMI were incubated at 37°C for
1 h before the addition of 5 ,ul of immune
spleen cell suspension. The plates were
incubated at 37°C under 5%o CO2 for 36 h
and processed as described previously.
Experimental design.-Five animals from
both control and tumour bearing groups
were processed as described on Days 12, 22,
23, 25, 28 and 34 following inoculation of
B16 melanoma. The control group consisted
of sex and age-matched non-tumour bearing
C57BL/6J mice. As foot amputation of
control mice did not significantly change
the cytotoxicity of cells from the regional
lymph node or spleen in this test system,
these animals were used as the source of
normal cells and sera.
On Day 22, mice were anaesthetized
with Nembutal and the left foot containing
the tumour was amputated. At this stage
the footpad had doubled in thickness. On
Day 23 only sera were collected. The
immune spleen cells used in blocking experi-
ments were obtained from mice with a
22-day tumour. Cytotoxicity (relative in-
hibition of tumour cell growth in vitro) was
expressed as a percentage, using the formula:
N - T/N x 100 (%) where N is the mean
number of B16 cells remaining per well with
lymphoid cells or serum from control animals
and T is the mean number of B16 cells
remaining per well with lymphoid cells or
serum from animals inoculated with tumour.
RESULTS
Spleen cell cytotoxicity rose from
insignificant levels on Day 12 to 23% on
Day 22 (Table I). Three days following
tumour excision the cytotoxicity in-
creased from 23 to 28% and was still
present at the end of the experiment,
12 days after tumour excision (Day 34).
Spleen cells from animals with a 22-day
tumour had no significant effect on LLT
cells.
The regional lymph node cells at no
time showed significant inhibition of
tumour cell growth in vitro and on Day
22 lymph node cells from tumour bearing
mice facilitated the growth of tumour
cells (Table I). It was observed that
the draining lymph nodes were enlarged
at this stage, but there were no B16
cells seen in tissue culture wells if the
lymph node cell suspension alone was
plated. This eliminated the possibility
that metastatic cells in the regional
lymph nodes were producing an artefactual
tumour growth stimulatory effect. Fol-
lowing tumour excision this effect was
lost within 3 days. Regional lymph
node cells from mice with a 22-day tumour
did not stimulate LLT cells in vitro.
TABLE 1.-Cell Mediated Cytotoxicity
Days
post-inoculation
12
22
22
25
28
34
12
22
22
25
28
34
Effector
cell
Spleen cells
Spleen cells
Spleen cells
Spleen cells
Spleen cells
Spleen cells
Lymph node
Lymph node
Lymph node
Lymph node
Lymph node
Lymph node
Target cell
B16
B16
LLT
B16
B16
B16
B16
B16
LLT
B16
B16
B16
No. of target cells/well
(mean±S.D.)
Normal Tumour bearing
24-0+4-0 22-342-2
16-6+2-8 12-7±1-9
28-6+3-2 303±40
29-1±5 0 20-8±5-1
30-4±2-9 24-8±4 1
76-9+3-8 62-9±6-6
27-6±4-0
11- 1 2-6
26-4±2 - 8
20 7±3 '9
22- 8±4 - 3
62 0±5-8
30-7±3-6
15* 3 ±3-3
27-2±3-1
22-3±4 - 2
19 9±4 1
62-8±5 3
* P < 001 by Student's " t " test.
Cytotoxicity
7 0
23-0*
-6-0
28-5*
18-0*
19-0*
-11.0 -33.0*
-3-0
-8 (0
13-0
-1 0
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TABLE II. Serum Cytotoxicity
No. of days
post-inoculation No. of B16
when sera cells/well %
collected (mean± S.D.) Cytotoxicity
0 46- 7+4- 5 0
12 36-1L6-6 23-0*
22 34* 1±4- 5 27.0*
23 31-0±5-5 33-6*
25 293±4-6 37.2*
28 32-6±6-6 30-2*
34 32-3±4-4 30-8*
*JP < 0 - 001 by Students " t " test.
Sera from tumour bearing mice were
cytotoxic to melanoma cells compared
with sera from control mice (Table II).
Serum cytotoxicity increased from 27%0
pre-operatively to a maximum of 37%
3 days after excision of the tumour.
The difference in serum cytotoxicity pre-
operatively to that 3 days post-operatively
was significant (P < 0.01). Serum cyto-
toxicity was still present 12 days after
tumour excision.
Sera from tumour bearing mice blocked
the cytotoxicity of immune spleen cells
in vitro (Table III); 24 h following tumour
excision, this blocking effect was not
observed and on Day 25, 3 days after
tumour excision, the sera increased spleen
cell cytotoxicity. This effect was still
present 12 days post excision. Normal
sera and sera from mice with a 1 cm
diameter LLT did not block spleen cell
cytotoxicity.
Ten mice from the experimental group
were followed for 3 months and no
evidence of recurrent tumour was ob-
served.
DISCUSSION
In this experimental model rapid
changes in the host immune response
occurred when a growing tumour was
excised. Most remarkable was the loss
of blocking factor from the serum within
24 h. This was more rapid than pre-
viously reported. Baldwin et al. (1]973)
observed blocking to disappear at 3
days; Heppner (1972) showed a slower
clearance in which blocking was more
consistently absent 10-15 days after
tumour excision. A likely explanation
for the rapid loss of blocking in this
study is that the tumours were excised
when they were smaller than those used
in the previous studies. Earlier work in
this laboratory has shown that there was
no spread of tumour to the regional
lymph nodes or lungs at this stage of
growth. As blocking activity is greatest
with large tumour loads, it is thus likely
to require a longer time for clearance
following tumour excision.
No direct evidence as to the nature
of the blocking factor has been elucidated
in this study. It would be most unlikely
TABLE III.-Serum, Blocking Factors
No. of days
post-inoculation No. of B16 cells/well % %
Effector cells when sera collected (mean+S.D.) Cytotoxicitv Blockingt
NSP 0 39-8 5-3 -
TSP 0 28 3±52 28-0*
TSP 12 37- 6±4- 0 5.-5* 81
TSP 22 38- 5±2- 0 3.0* 90
TSP 23 30-0±31 25-() 10
TSP 25 26-3 ±4- 8 34- 0 -17
TSP 28 26-1+5- 1 34- 0 -17
TSP 34 26- 2±3 - 9 34 0 -17
TSP LLT sera 29-2±2-8 26-6 5
NSP = Spleen cells from controls.
TSP = Spleen cells from tumour bearing mice.
* P < 0-001 by Student's
" t
" test.
t Calculation for % blocking:
00 cytotoxicity with normal sera- % cytotoxicity wvith test sera
% cytotoxicity with normal sera
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that the blocking factor was antibody
alone, because cytotoxic antibody activity
was greatest following excision when no
blocking was detectable. The rapid loss
of blocking and increase in cytotoxic
antibody level following tumour excision
could be explained equally well if the
blocking factor was an antigen-antibody
complex (Sjogren et al., 1971) or tumour
anitigen, as was first demonstrated by
Currie and Basham (1972).
The rise in cytotoxic antibody titre
following tumour excision may have been
due to a continuing antibody production
in the absence of tumour cells which
could have bound the antibody or which
could have released antigen into the
circulation with the formation of antigen-
antibody complexes. Because low anti-
body titres were found in the thoracic
duct lymph of tumour bearing animals,
Thompson, Steele and Alexander (1973)
considered that antigen was released
from the tumour cell before being bound
by antibody. The rise in antibody titre
may enable residual tumour cells to be
destroyed either directly by fixing
complement or by activating a cell
mediated response (Basham and Currie,
1,974).
On the basis of in vivo studies, Prehn
(1972) has postulated that a weak cell
mediated immunity may directly stimu-
late tumour growth. In vitro evidence
for " immunostimulation " has recently
been reported (Medina and Heppner,
1972; Fidler, 1973; Bartholomaeus et
al., 1974) in lymph node lymphocytes.
Flannery et al. (1973), using a rat squa-
mous cell carcinoma, demonstrated region-
al lymph node cytotoxicity that disap-
peared with tumour growth, although
peripheral lymphocyte cytotoxicity was
still present. They attributed the loss
of cytotoxicity to increased levels of
blocking factor acting in association with
an increase in tumour growth. It is
possible that a similar mechanism is
operative in this experimental model as
lymph node stimulation oftumour growth
by regional lymph node cells disappeared
following the loss of serum blocking
factor after the tumour was excised.
It is not considered that the regional
lymph node lymphocytes directly stimu-
late tumour cell growth in vitro. A
more reasonable explanation is that the
regional lymph node cells have attached
blocking factor which is not removed by
the conventional 3 washings in PBS as
previously demonstrated by Currie and
Basham (1972) in patients with advanced
tumour growth. In tissue culture this
blocking factor inhibits lymphocyte reac-
tivity. However, as the control lymph
node cells reduce the number of melanoma
cells in each tissue culture well over the
36 h incubation period, the net result is
an apparent stimulation of tumour
growth.
These findings provide in vitro evi-
dence to support the work of Alexander et
al. (1969). They found that the regional
lymph node appeared quite active histo-
logically, although there were no in-
creased numbers of immunoblasts in the
draining lymph. After tumour excision
there was a rapid rise of immunoblasts
in the lymph while the regional lymph
nodes returned to a normal histological
appearance. The suggestion that tumour
antigen produced a selective depression
on the regional lymph nodes' responsive-
ness would agree with current views on
the nature of blocking (Currie, 1973) and
results obtained from this study.
It would appear that the changes in
host immunity observed are directly
related to removal of the source of
tumour antigen, leading to loss of serum
blocking and a rise in serum cytotoxicity.
Associated with the loss of high concen-
trations ofblocking factor locally, regional
lymph node stimulation oftumour growth
disappeared. If these in vitro findings
are directly applicable to the in vivo
situation, it would suggest that tumour
excision confers a number of beneficial
effects on the host; the major effect
being loss of serum blocking factor in the
presence of a continuing cell mediated im-
munity inhibitory to tumour cell growth.
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